Monitoring heart failure
US7319017B2 · kind B2 · utility
4Cited by
1References
10Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jul 13, 2005 |
| Grant date | Jan 15, 2008 |
| Priority date | — |
| Expiry date | Jul 13, 2025 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S435/81
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
An in vitro method for identifying subjects at risk of heart failure following a Myocardial Infarction comprising analyzing the concentration of Matrix Metalloproteinase-9 in a bodily sample from a subject who has suffered a Myocardial Infarction and comparing this concentration with a reference for concentrations of Matrix Metalloproteinase-9 in individuals who have not suffered a Myocardial Infarction; wherein a raised concentration of Matrix Metalloproteinase-9 in the bodily sample from a subject who has suffered a Myocardial Infarction suggests the subject is at risk of heart failure.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.